Is Shukra Pharma. overvalued or undervalued?

As of 7 May 2024, the valuation grade for Shukra Pharma. has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE Ratio of 63.03, an EV to EBITDA of 46.20, and a Price to Book Value of 11.12, all of which are substantially higher than industry averages.
In comparison to its peers, Shukra Pharma.'s PE Ratio is notably higher than Sun Pharma. (35.25) and Cipla (22.99), which are categorized as expensive and attractive, respectively. Additionally, while Divi's Lab is also classified as very expensive with a PE of 79.33, Shukra Pharma. still stands out with a significantly lower PEG Ratio of 0.00, suggesting a lack of growth expectations. Notably, Shukra Pharma. has outperformed the Sensex over the past year with a return of 54.08% compared to the Sensex's 7.65%, further complicating its valuation narrative.